Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive intravitreal Avastin (bevacizumab) to prevent early postoperative vitreous haemorrhage after diabetic vitrectomy
2007-000780-21Phase 4Terminated
- Sponsor
- Moorfields Eye Hospital
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of bevacizumab in Vitreous hemorrhage (VH) and proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Moorfields Eye Hospital. Primary endpoint: Frequency of vitreous haemorrhage within 6 months after operation. Started Oct 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
Vitreous hemorrhage (VH)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2007-000780-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000780-21.